Related Experiment Video
Updated: May 24, 2026
12:03
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Comparative activity of carbapenem testing (the COMPACT study) in Turkey
Hakan Leblebicioglu1, Nedim Cakir, Mustafa Celen
1Ondokuzmayis University, Kurupelit Kampüsü, Samsun, Turkey. hakanomu@omu.edu.tr
BMC Infectious Diseases
|February 21, 2012
Summary
Doripenem demonstrated comparable or superior in vitro activity against Gram-negative pathogens compared to meropenem and imipenem in Turkish hospitals. This finding is crucial for guiding antibiotic selection in treating serious hospital-acquired infections.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Gram-negative bacterial infections, including Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are significant causes of hospital-acquired infections.
- Carbapenem antibiotics are vital for treating these infections, necessitating ongoing surveillance of their efficacy.
Purpose of the Study:
- To evaluate the in vitro activity of doripenem against Gram-negative clinical isolates in Turkey.
- To compare doripenem's efficacy with other carbapenems like meropenem and imipenem.
Main Methods:
- Ten centers in Turkey collected Gram-negative isolates from patients with various severe infections between May and October 2008.
- Isolate susceptibility testing was performed using E-test, with central laboratory confirmation and quality control.
Main Results:
- Doripenem exhibited MIC90 values of 32 mg/L for Pseudomonas spp., 0.12 mg/L for Enterobacteriaceae, and ≥64 mg/L for other Gram-negative isolates.
- Compared to meropenem and imipenem, doripenem showed similar or better activity across the tested Gram-negative pathogens.
- Higher MIC90 values were observed for intensive care unit (ICU) isolates compared to non-ICU isolates.
Conclusions:
- Doripenem demonstrated favorable in vitro activity against Gram-negative pathogens in Turkey.
- Doripenem showed comparable or superior efficacy to meropenem and imipenem, suggesting its potential role in treating hospital-acquired infections caused by these pathogens.
